135 related articles for article (PubMed ID: 10215835)
21. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
Graeber GM; Gupta NC; Murray GF
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
[TBL] [Abstract][Full Text] [Related]
22. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.
Evilevitch V; Weber WA; Tap WD; Allen-Auerbach M; Chow K; Nelson SD; Eilber FR; Eckardt JJ; Elashoff RM; Phelps ME; Czernin J; Eilber FC
Clin Cancer Res; 2008 Feb; 14(3):715-20. PubMed ID: 18245531
[TBL] [Abstract][Full Text] [Related]
23. A PET study of 18FDG uptake in soft tissue masses.
Lodge MA; Lucas JD; Marsden PK; Cronin BF; O'Doherty MJ; Smith MA
Eur J Nucl Med; 1999 Jan; 26(1):22-30. PubMed ID: 9933658
[TBL] [Abstract][Full Text] [Related]
24. Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography.
Schwarzbach M; Willeke F; Dimitrakopoulou-Strauss A; Strauss LG; Zhang YM; Mechtersheimer G; Hinz U; Lehnert T; Herfarth C
Anticancer Res; 1999; 19(2B):1343-9. PubMed ID: 10365104
[TBL] [Abstract][Full Text] [Related]
25. 18FDG PET scanning of benign and malignant musculoskeletal lesions.
Feldman F; van Heertum R; Manos C
Skeletal Radiol; 2003 Apr; 32(4):201-8. PubMed ID: 12652335
[TBL] [Abstract][Full Text] [Related]
26. PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin.
Katal S; Gholamrezanezhad A; Kessler M; Olyaei M; Jadvar H
PET Clin; 2018 Oct; 13(4):609-621. PubMed ID: 30219191
[TBL] [Abstract][Full Text] [Related]
27. Quantitative dynamic ¹⁸FDG-PET and tracer kinetic analysis of soft tissue sarcomas.
Rusten E; Rødal J; Revheim ME; Skretting A; Bruland OS; Malinen E
Acta Oncol; 2013 Aug; 52(6):1160-7. PubMed ID: 23198721
[TBL] [Abstract][Full Text] [Related]
28. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis.
Ioannidis JP; Lau J
J Nucl Med; 2003 May; 44(5):717-24. PubMed ID: 12732672
[TBL] [Abstract][Full Text] [Related]
29. Functional image in soft tissue sarcomas: An update of the indications of
Rodríguez-Alfonso B; Simó-Perdigó M; Orcajo Rincón J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):233-243. PubMed ID: 32616457
[TBL] [Abstract][Full Text] [Related]
30. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S
Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
[TBL] [Abstract][Full Text] [Related]
31. FDG-PET for evaluating musculoskeletal tumors: a review.
Aoki J; Endo K; Watanabe H; Shinozaki T; Yanagawa T; Ahmed AR; Takagishi K
J Orthop Sci; 2003; 8(3):435-41. PubMed ID: 12768492
[TBL] [Abstract][Full Text] [Related]
32. [Positron emission tomography with fluorine-deoxyglucose in sarcomas and non-sarcoma non-epithelial tumors].
Massardo T; Jofré MJ; Sierralta MP; Canessa J; Castro G; Berrocal I; Gallegos I
Rev Med Chil; 2012 Sep; 140(9):1116-25. PubMed ID: 23354632
[TBL] [Abstract][Full Text] [Related]
33. [Biologic characterization of soft tissue sarcomes by positron emission tomography (initial results)].
Schwarzbach M; Willeke F; Dimitrakopoulou-Strauss A; Strauss LG; Mechtersheimer G; Hinz U; Lehnert T; Herfarth C
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):635-9. PubMed ID: 14518332
[TBL] [Abstract][Full Text] [Related]
34. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
35. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas.
Iagaru A; Chawla S; Menendez L; Conti PS
Nucl Med Commun; 2006 Oct; 27(10):795-802. PubMed ID: 16969262
[TBL] [Abstract][Full Text] [Related]
36. The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas.
Kasper B; Hohenberger P; Strauss LG; Dimitrakopoulou-Strauss A
Hell J Nucl Med; 2010; 13(1):40-4. PubMed ID: 20411170
[TBL] [Abstract][Full Text] [Related]
37. Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors.
Bischoff M; Bischoff G; Buck A; von Baer A; Pauls S; Scheffold F; Schultheiss M; Gebhard F; Reske SN
Arch Orthop Trauma Surg; 2010 Jul; 130(7):819-27. PubMed ID: 19636577
[TBL] [Abstract][Full Text] [Related]
38. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose.
Kole AC; Nieweg OE; van Ginkel RJ; Pruim J; Hoekstra HJ; Paans AM; Vaalburg W; Koops HS
Ann Surg Oncol; 1997 Jan; 4(1):57-63. PubMed ID: 8985518
[TBL] [Abstract][Full Text] [Related]
39. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions.
Maurea S; Mainolfi C; Bazzicalupo L; Panico MR; Imparato C; Alfano B; Ziviello M; Salvatore M
AJR Am J Roentgenol; 1999 Jul; 173(1):25-9. PubMed ID: 10397094
[TBL] [Abstract][Full Text] [Related]
40. The role of 18F-FDG PET/CT in soft tissue sarcoma.
Sambri A; Bianchi G; Longhi A; Righi A; Donati DM; Nanni C; Fanti S; Errani C
Nucl Med Commun; 2019 Jun; 40(6):626-631. PubMed ID: 30908341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
